Lovenox 30 mg Twice Daily (BID) Versus 40 mg Once Daily (QD) — Stella

Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

About Browse conditions ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

Lovenox 30 mg Twice Daily (BID) Versus 40 mg Once Daily (QD) — Stella

View on ClinicalTrials.gov

Recruiting

Back to Trauma trials

Phase 4 — Post-approval study. The treatment has been approved, but researchers continue monitoring it in a large population over time.

Trial locations(1 site)

United States

Oregon Health & Science University, Portland, Oregon

Key details

Phase

Post-approval study

Sponsor

Oregon Health and Science University

Enrollment target

~606 participants

Started

February 2014

Primary completion

December 2024

This trial's estimated completion date has passed — the record may not be fully up to date.

Age range

15 Years – 100 Years

Last updated April 2024

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Stella acts as an intermediary. Researcher contact info is never exposed.

Follow this trial

Get notified in plain English when this trial's status changes. No account required.